{"nctId":"NCT01993888","briefTitle":"The EVARREST® Fibrin Sealant Patch Liver Study","startDateStruct":{"date":"2013-10"},"conditions":["Hemorrhage"],"count":102,"armGroups":[{"label":"EVARREST® Fibrin Sealant Patch","type":"EXPERIMENTAL","interventionNames":["Biological: EVARREST® Fibrin Sealant Patch"]},{"label":"Standard of Care (SoC)","type":"OTHER","interventionNames":["Other: Standard of Care (SoC)"]}],"interventions":[{"name":"EVARREST® Fibrin Sealant Patch","otherNames":[]},{"name":"Standard of Care (SoC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects ≥ 18 years of age, requiring elective or urgent, open hepatic surgery.\n* Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon\n* Subjects or legally authorized representatives must be willing to participate in the study, and provide written informed consent. (Note: This criteria does allow for hospital translators to be used where approved by Ethics Committees/Institutional Review Boards)\n\nExclusion Criteria:\n\n* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;\n* TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of EVARREST® to blood flow and pressure during healing and absorption of the product;\n* TBS with major arterial bleeding requiring suture or mechanical ligation;\n* Subjects admitted for trauma surgery;\n* Subject is a transplant patient for fulminant hepatic failure\n* Subject with TBS within an actively infected field;\n* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine;\n* Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;\n* Subjects who are known, current alcohol and / or drug abusers;\n* Subjects who have participated in another investigational medical device or investigational drug trial within 30 days of surgery or are expected to participate in another medical device or investigational drug trial during the course of the study;\n* Female subjects who are pregnant or nursing.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization","description":"Proportion of subjects achieving hemostasis at the TBS at 4-minutes following randomization and with no re-bleeding requiring treatment at the TBS any time prior to initiation of wound closure. Hemostasis is defined as no detectable bleeding at the TBS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemostasis at the Target Bleeding Site (TBS) at 10-minutes Following Randomization","description":"Proportion of subjects achieving hemostatic success at 10 minutes following randomization and no further bleeding requiring treatment prior to initiation of wound closure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Time to Hemostasis","description":"The absolute time to achieve hemostasis at or after 4 minutes from randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Re-bleeding Events From the TBS During the Study Follow-up","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events (AEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events That Were Potentially Related to Thrombotic Events","description":"Number of participants with adverse events that were potentially related to thrombic events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":50},"commonTop":["Nausea","Constipation","Hypotension","Vomiting","Pyrexia"]}}}